Previous reports showed that CX-4945 can sensitize head and neck cancer to MEK inhibitors and MEK inhibition has been shown to slow MPNST tumor growth [71, 16]. This evidence concerns the gene MAP2K7 and malignant peripheral nerve sheath tumor.